Techcyte, Inc.
PrivateLast Round
VC Round
Apr 30, 2026
Total Funding Raised
$34.61M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Techcyte, Inc. is a healthtech company that provides an AI-powered digital pathology platform for anatomic and clinical pathology.
Sector
Healthcare & Life Sciences
Verticals
Medical AI, Medical Imaging, Computer Vision, Vertical SaaS, Healthcare Analytics
Business Model
B2B
Customer Profile
Subscription SaaS, Usage-Based SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Techcyte, Inc. Comparables
Compare Techcyte, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Proscia | 87% | |
| Deciphex | 84% | |
| AIRA Matrix | 84% |
Techcyte, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Apr 30, 2026 | ||||
| VC Round | Jan 11, 2024 | ||||
| Series E | Aug 18, 2021 | ||||
| Seed | Jan 18, 2018 | ||||
| Series A | Jan 18, 2018 | ||||
Seed | Mar 1, 2016 |
Techcyte, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Mayo Clinic Ventures | VC Round |
| Van Tuyl Companies | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 45% MoM.
- Jul 20, 2026
Open roles increased to 32, representing 27% of headcount.
Recent news
Latest coverage and updates
- launchesOct 16, 2026
Techcyte announces that AI-guided macrodissection for NGS preparation is now available on Techcyte Fusion AP in Utah on Oct 16th '26, using Aignostics' HETA Tumor Cellularity to help pathology teams identify tumor-rich regions, assess tumor cellularity, and guide tissue scraping for downstream molecular testing.
- launchesOct 15, 2026
Techcyte launches a per-slide Digital Pathology bundle combining the Techcyte Fusion AP platform, Epredia slide scanners, service and maintenance, and cloud storage through Fisher Healthcare in Utah on Oct 15th '26.
- attends_eventSep 8, 2026
Techcyte, Inc. participates in the Strategic Supplier Summit in Utah on Sep 8th '26, where it receives the 2026 Innovation Award from Sonora Quest Laboratories.
- partners_withAug 14, 2026
Techcyte, Inc. and Elea.ai GmbH partner to bring AI-native documentation intelligence into Techcyte Fusion, enabling pathologists to turn assessments into structured, coded reports in Utah on Aug 13th '26.
Techcyte, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Techcyte, Inc.'s valuation, stock price, and market status.
Is Techcyte, Inc. a public or private company?
Techcyte, Inc. is a private company.
What is the current stock price of Techcyte, Inc.?
Techcyte, Inc. is a private company, so its shares have no public market price. Caplight tracks Techcyte, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Techcyte, Inc. worth (valuation)?
Valuation information for Techcyte, Inc. is not publicly available.
Can I buy Techcyte, Inc. stock?
Techcyte, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Techcyte, Inc.'s last funding round?
Techcyte, Inc.'s most recent funding round was VC Round on April 30, 2026.
Who are the main investors in Techcyte, Inc.?
Key investors in Techcyte, Inc. include Van Tuyl Companies.
Will Techcyte, Inc. IPO soon?
No public IPO plans have been announced for Techcyte, Inc..
How can I track Techcyte, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Techcyte, Inc.'s shares on secondary markets.